PMH6 A COMPARATIVE REVIEW OF SAFETY, EFFICACY AND ECONOMICS OF OFF-LABEL PRESCRIBING OF LEADING ATYPICAL ANTIPSYCHOTICS  by Mittal, AR
Abstracts A173
toms as depression is poorer among ethnic minorities than among whites. Patient and
physician education campaigns aimed at addressing the cultural stigma and percep-
tions of depression as well as available treatment options available may increase likeli-
hood of diagnosis and possibly lead to better outcomes.
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OBJECTIVES: To assess the prevalence of depression among ﬁ ve large European
nations. METHODS: TNS Healthcare’s European Healthcare Panel of individuals in
France, Germany, Italy, UK and the Netherlands were surveyed in 2007 to assess 
disease burden at national level. The self-reported epidemiological data is representa-
tive of population gender and age (18–24, 25–34, 35–44, 45–54, 55–64, 65–69 yrs) 
strata in respective countries, ensured by sampling and intensive panel management.
The survey collected information on select health conditions (incl. depression; in the 
past 12-months), quality of life and health care-utilization. RESULTS: In the TNS
European Healthcare Panel, 8,665, 25,265, 19,887, 59,850 and 47,340 individuals 
completed survey in the Netherlands, Germany, Italy, France and UK respectively. 
Prevalence of Depression varied widely between these 5 nations, as follows: Nether-
lands: 9.4%, Germany: 14.6%, U.K: 14.8%, France: 17.8%, Germany: 18.8%.
Within each country, burden of Depression varied by age and gender; distribution 
among male (18–24, 25–34, 35–44, 45–54, 55–64, 65 yrs: % pts) was: the Nether-
lands: 5.1%, 6.0%, 7.0%, 7.6%, 7.3%, 5.1%; Germany: 10.9%, 9.9%, 11.2%, 
13.7%, 10.6%, 3.7%; Italy: 9.9%, 7.4%, 9.5%, 10.9%, 11.3%, 9.4%; France: 
13.7%, 12.8%, 14.4%, 14.6%, 10.9%, 6.2%; U.K: 11.8%, 12.2%, 15.8%, 18.7%,
14.0%, 7.0%; distribution among female (18–24, 25–34, 35–44, 45–54, 55–64, 65
yrs: % pts) was: the Netherlands: 5.7%, 14.4%, 13.4%, 13.3%, 10.9%, 13.8%;
Germany: 18.9%, 17.9%, 19.8%, 24.2%, 16.0%, 8.2%; Italy: 17.7%, 17.7%, 
21.1%, 24.7%, 21.3%, 12.2%; France: 25.4%, 23.4%, 23.0%, 23.7%, 19.5%, 
15.5%; UK: 24.9%, 24.8%, 26.6%, 26.2%, 19.1%, 12.8%. General Practitioners
were the primary point of diagnosis and source of treatment, even though this statistic
varied between the countries. CONCLUSIONS: Prevalence of depression appears to
be substantial in the studied European nations and peaked in the 35–55 age-group.
Females had substantially higher disease burden, amounting to as much as twice as 
their male counterparts in certain age groups.
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OBJECTIVES: The pediatric Quality of Life Enjoyment and Satisfaction Question-
naire (PQ-LES-Q) is made up of 14 items that assess quality of life (QoL) aspects
(Total) and a 1-item overall assessment (Overall). This post-hoc analysis determined 
whether patient’s assessment in QoL correlated with improvement as determined by 
the clinical assessment (i.e. PANSS; CGI-S). METHODS: A total of 302 patients (aged 
13–17) with schizophrenia participated in a 6-week, multicenter, double-blind, ran-
domized trial. The primary measure was mean change from baseline in PANSS Total
score (LOCF). Secondary measures included CGI-S and the PQ-LES-Q Total and
Overall. Relationships between percentage of change from baseline in PQ-LES-Q. 
Total and percentage of change in PANSS and between change from baseline in PQ-
LES-Q Total and change from baseline in CGI-S score were tested by Pearson correla-
tion and trend analysis (Cochran-Mantel-Haenszel). RESULTS: Aripiprazole showed
signiﬁ cant improvements over placebo in PANSS, CGI-S, and PQ-LES-Q Overall
(week 6; p  0.05; LOCF). Strong correlation was found between all measures in 
the overall population, including PQ-LES-Q Total versus PANSS Total score and PQ-
LES-Q Overall versus CGI-S (r  0.33 and 0.29; p  0.01). Analysis by treatment 
arm showed strong correlation between change in PQ-LES-Q Total versus change in 
PANSS Total in all groups (r  0.44; p  0.011; LOCF). Correlation between change
in PQ-LES-Q Overall versus change in CGI-S was signiﬁ cant in the 10 mg/day group 
(r  0.33; p  0.001; LOCF), but not for the 30 mg/day and placebo groups (r 
0.084). Categories of CGI-S and PANSS Total improvement correlated with change
in PQ-LES-Q (p  0.001; LOCF). CONCLUSIONS: Improvements in patient-assessed 
QoL were signiﬁ cantly correlated with clinician reported outcomes in the overall
population and in individual treatment groups. Aripiprazole 10 mg/day and the com-
bined treatment group demonstrated a signiﬁ cant correlation between improvements 
in global QoL and global severity of illness.
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OBJECTIVES: To examine the controversial practice of off-label prescribing of atypi-
cal antipsychotic drugs and to review research evidence pertaining to the economics 
of their use, safety, efﬁ cacy and appropriateness of such prescribing. METHODS: A
comprehensive review of scientiﬁ c literature published between 2001–2009, covering
all empirical studies that examined off-label prescribing of atypical antipsychotics. 
Quantitative and qualitative analyses of published secondary data for off-label uses 
of three leading atypical anti-psychotics were conducted to gain insights into preva-
lence of off-label use, costs, and mortality associated with their use. RESULTS: Twenty 
experimental and observational studies qualiﬁ ed for inclusion. Most study participants
were institutionalized elderly, Caucasian men, with Alzheimer’s disease. The newer 
atypicals accounted for more than $11 billion in annual sales and represented 90% 
of the antipsychotic market in 2005. There was a ﬁ ve-fold increase in the prescription
of these drugs particularly in children in the last decade and a half. Risperidone was
the most prescribed drug off-label. EPS, gait disturbances and weight gain were the 
most commonly cited adverse events. Elderly patients with dementia-related psychosis 
treated with atypical antipsychotics were found to be at an increased risk of adverse
events and death. CONCLUSIONS: The research evidence available to determine the
true extent and consequences of off-label prescribing of atypical antipsychotics, while 
scarce and conﬂ icting, is mostly critical of their use in children and elderly with 
dementia. Scientiﬁ c support documenting the efﬁ cacy and appropriateness of these 
drugs for treating depression and behavioral disorders of dementia is currently incon-
clusive. The high cost of these drugs may arguably offset the advantages stemming 
from their perceived lower side-effect proﬁ le.
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OBJECTIVES: The pediatric Quality of Life Enjoyment and Satisfaction Question-
naire (PQ-LES-Q) is made up of 14 items that assess aspects of quality of life (Total) 
and a 1-item overall assessment (Overall). Quality of Life measures yield information 
independent of symptom measures. This post-hoc analysis investigated correlation 
between patient’s QoL assessment and objective clinical assessment (YMRS, CGI-BP). 
METHODS: A total 296 children (age 10–17) with bipolar disorder participated in a 
4-week double-blind trial of aripiprazole (10 or 30 mg/day, ﬁ xed doses) vs. placebo 
(PBO). Completers entered a 26 week extension. Primary outcome was mean change 
on YMRS Total Score. Secondary measures included mean changes on CGI-BP
Overall, PQ-LES-Q Total (T) and the Overall item (O). RESULTS: YMRS Total and 
CGI-BP Overall improved vs. PBO with both doses of aripiprazole at week 4 and 
week 30 (p  0.05 and p  0.01 respectively, LOCF). Both aripiprazole arms improved 
on PQ-LES-Q(T) and (O); however they did not reach statistical signiﬁ cance. Observed 
Cases analysis (OC) demonstrated a correlation at week 4 and week 30 between % 
change in PQ-LES-Q(T) and % change in YMRS (r  0.18 and 0.29, respectively; 
p  0.03). When 4 week YMRS Total improvement was put into categories (20%; 
20–30%; 30–50%; 50% reduction), % change in mean PQ-LES-Q(T) was 1.7, 2.3, 
12.5, & 10.4 per category (trend analysis p  0.007; regression p  0.01; OC). At 30 
weeks % change in mean PQ-LES-Q(T) was 3.3, NA, 2.6, 16.6 (p  0.02; Linear
regression p  0.02; OC). When CGI-BP Overall was put into 4 categories ( 0; 1; 
2; a3 point change) at 4 weeks, % change in mean PQ-LES-Q(O) was 0.02, 0.15, 
0.27, 0.43 per category (trend analysis p  0.05; OC) and at 30 weeks, % change in
mean PQ-LES-Q(O) was 1, 0, 0.63, 0.64 (p  0.02; OC). CONCLUSIONS: In this
trial of pediatric patients with BP there was positive correlation between patient-
assessed QoL measures and clinician-based assessment.
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OBJECTIVES: Antipsychotic drugs are widely used and costly. Little is known 
about how this has varied based on clinical applications and levels of evidence. 
METHODS: We used the IMS Health National Disease and Therapeutic Index to 
describe typical and atypical antipsychotic use from 1994 through 2007. We linked
this nationally representative cross-sectional data from outpatient physician practices 
to levels of evidence and FDA approval status from the FDA and the Drugdex
drug compendium. We obtained promotional and prescription expenditures from
IMS Health Integrated Promotional Services and the National Prescription Audit.
RESULTS: Preliminary results suggest aggregate annual antipsychotic use increased 
262% from 8 million physician visits (1994) to 21 million (2006), then declined to
19 million (2007). The market share of typical antipsychotics decreased from 86%
to 8% over this time period. Large increases in antipsychotic use occurred among 
individuals 18–64 (234%) and 18 years of age (559%). Increases were more modest
among those 65 years of age or older (131%). Antipsychotic use for schizophrenia
